ACM
KLRS

Aquatic Capital Management’s Kalaris Therapeutics KLRS Stock Holding History

Aquatic Capital Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-543
Closed -$64K – 1832
2022
Q4 		$64K Buy
+543
New +$92.1K ﹤0.01% 962

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Aquatic Capital Management's KLRS Position: Q1 2023 in Review

Aquatic Capital Management sold out of Kalaris Therapeutics (KLRS) in Q1 2023, closing a stake of 543 shares — an estimated $64K sold.

Aquatic Capital Management first reported a position in KLRS in Q4 2022 and held it in 1 quarter. The position peaked at $64K in Q4 2022. 89 funds tracked by Wall St. Rank hold KLRS as of Q1 2023.

  • Aquatic Capital Management reported no remaining Kalaris Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Aquatic Capital Management sold 543 Kalaris Therapeutics shares in Q1 2023, an estimated $64K.
  • Aquatic Capital Management first reported a position in Kalaris Therapeutics in Q4 2022 and held it in 1 quarter.
  • Aquatic Capital Management's Kalaris Therapeutics position peaked at $64K in Q4 2022.
  • 89 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2023.

Based on Aquatic Capital Management's 13F filing for Q1 2023, filed 15 May 2023.